ARISTO

Aristo Bio-Tech and Lifescience Share Price

₹130.00 -8 (-5.8%)

19 May, 2025 13:14

SIP TrendupStart SIP in ARISTO

Start SIP

Performance

  • Low
  • ₹130
  • High
  • ₹130
  • 52 Week Low
  • ₹63
  • 52 Week High
  • ₹164
  • Open Price₹130
  • Previous Close₹138
  • Volume1,600

Investment Returns

  • Over 1 Month -2.69%
  • Over 3 Month + 23.81%
  • Over 6 Month -5.39%
  • Over 1 Year + 63.01%
SIP Lightning

Smart Investing Starts Here Start SIP with Aristo Bio-Tech and Lifescience for Steady Growth!

Invest Now

Aristo Bio-Tech and Lifescience Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 22.7
  • PEG Ratio
  • -
  • Market Cap Cr
  • 89
  • P/B Ratio
  • 2.6
  • Average True Range
  • 6.18
  • EPS
  • 5.72
  • Dividend Yield
  • 0
  • MACD Signal
  • 3.94
  • RSI
  • 51
  • MFI
  • 39.48

Aristo Bio-Tech and Lifescience Financials

Aristo Bio-Tech and Lifescience Technicals

EMA & SMA

Current Price
₹130.00
-8 (-5.8%)
pointer
  • stock-down_img
  • Bearish Moving Average 7
  • stock-up_img
  • Bullish Moving Average 9
  • 20 Day
  • ₹130.31
  • 50 Day
  • ₹126.23
  • 100 Day
  • ₹123.50
  • 200 Day
  • ₹114.91

Resistance and Support

130 Pivot Speed
  • R3 130.00
  • R2 130.00
  • R1 130.00
  • S1 130.00
  • S2 130.00
  • S3 130.00

What's your outlook on Aristo Bio-Tech and Lifescience?

You can only vote for once

Ratings

Master Rating

EPS Strenth

N/A

Price Strength

Buyer Demand

Group Rank

Aristo Bio-Tech And Lifescience has an operating revenue of Rs. 809.98 Cr. on a trailing 12-month basis. An annual revenue growth of 12% is good, Pre-tax margin of 2% needs improvement, ROE of 11% is good. The company has a reasonable debt to equity of 30%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 9% and 13% from 50DMA and 200DMA. It is currently FORMING a base in its weekly chart and is trading around 12% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 0 which is a POOR score indicating inconsistency in earnings, a RS Rating of 87 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 29 indicates it belongs to a strong industry group of Chemicals-Agricultural and a Master Score of C is fair but needs to improve. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Aristo Bio-Tech and Lifescience Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-13 Quarterly Results & Others To consider other business matters.
2024-05-27 Audited Results & Dividend
2023-11-07 Quarterly Results
2023-05-27 Audited Results & Dividend
Date Purpose Remarks
2023-09-15 FINAL Recommended Final Dividend of 0.25 per equity share
View More

Aristo Bio-Tech and Lifescience F&O

Aristo Bio-Tech and Lifescience Shareholding Pattern

73.42%
23.1%
3.48%

About Aristo Bio-Tech and Lifescience

  • NSE Symbol
  • ARISTO
  • BSE Symbol
  • Chairman & Managing Director
  • Mr. Narendra Singh Barhat
  • ISIN
  • INE082101010

Similar Stocks to Aristo Bio-Tech and Lifescience

Aristo Bio-Tech and Lifescience FAQs

Aristo Bio-Tech and Lifescience share price is ₹130 As on 19 May, 2025 | 13:00

The Market Cap of Aristo Bio-Tech and Lifescience is ₹88.5 Cr As on 19 May, 2025 | 13:00

The P/E ratio of Aristo Bio-Tech and Lifescience is 22.7 As on 19 May, 2025 | 13:00

The PB ratio of Aristo Bio-Tech and Lifescience is 2.6 As on 19 May, 2025 | 13:00

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23